Commitments and Contingencies (Details Narrative)
|
|
|
9 Months Ended |
|
|
Nov. 03, 2020 |
Dec. 13, 2019
USD ($)
$ / shares
shares
|
Dec. 13, 2019
EUR (€)
shares
|
Sep. 30, 2021
USD ($)
|
Sep. 30, 2021
EUR (€)
|
Sep. 30, 2021
EUR (€)
|
Dec. 31, 2020
USD ($)
|
Total Long-Term Debt |
|
|
|
$ 2,787,389
|
|
|
|
Compensation expenses |
|
|
|
219,077
|
|
|
|
Stock option expenses |
|
|
|
190,981
|
|
|
|
Payments for future research and collobration |
|
|
|
932,999
|
|
|
|
Short term lease costs |
|
|
|
58,720
|
|
|
|
Aggerate amount payable, description |
the Company to pay in aggregate of up to $2.9 million over a period of 22 months.
|
|
|
|
|
|
|
Operating lease right-of-use assets |
|
|
|
263,440
|
|
|
$ 326,085
|
Managing Director's Agreement [Member] |
|
|
|
|
|
|
|
Amount payable |
|
|
|
229
|
|
|
|
Royalty payment |
|
|
|
$ 41,677
|
|
|
|
Royality |
|
|
|
6.00%
|
6.00%
|
|
|
Stock based compensation expenses |
|
|
|
$ 753,000
|
|
|
|
Stock Incentive Plan [Member] |
|
|
|
|
|
|
|
Restricted stock |
|
|
|
460,191
|
|
|
|
Total of stock option |
|
|
|
$ 926,640
|
|
|
|
Founder [Member] | Managing Director's Agreement [Member] |
|
|
|
|
|
|
|
Fixed interest rate |
|
|
|
6.00%
|
|
6.00%
|
|
In 2018 [Member] | Walloon Region Government [Member] | Colorectal Cancer Research Agreement [Member] |
|
|
|
|
|
|
|
Amount payable |
|
|
|
$ 124,270
|
|
|
|
Terms of agreement description |
|
|
|
The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received.
|
The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received.
|
|
|
Repayment of grants | € |
|
|
|
|
|
€ 181,500
|
|
Grant receivable | € |
|
|
|
|
|
605,000
|
|
In 2018 [Member] | University of Taiwan [Member] | Clinical Study Research Agreement [Member] |
|
|
|
|
|
|
|
Collaborative obligations amount due |
|
|
|
$ 510,000
|
|
|
|
Lease agreement expire period |
|
|
|
3 years
|
3 years
|
|
|
Collaborative obligations amount |
|
|
|
$ 2,550,000
|
|
|
|
In 2018 [Member] | BNP Paribas leasing solutions [Member] | Finance Lease Obligations [Member] |
|
|
|
|
|
|
|
Amount payable |
|
|
|
$ 3,896
|
|
|
|
Purchase price for the property | € |
|
|
|
|
|
€ 25,000
|
|
Maturity date |
|
|
|
Jan. 31, 2022
|
Jan. 31, 2022
|
|
|
Implicit interest |
|
|
|
1.35%
|
|
1.35%
|
|
Leased equipment amortized term |
|
|
|
5 years
|
5 years
|
|
|
In 2010 [Member] | Walloon Region Government [Member] |
|
|
|
|
|
|
|
Amount payable |
|
|
|
$ 63,673
|
|
|
|
Terms of agreement description |
|
|
|
it is due to pay a 6% royalty on such revenue to the Walloon Region.
|
it is due to pay a 6% royalty on such revenue to the Walloon Region.
|
|
|
Repayment of grants | € |
|
|
|
|
|
€ 314,406
|
|
In 2020 [Member] | Walloon Region Government [Member] |
|
|
|
|
|
|
|
Amount payable |
|
|
|
$ 59,836
|
|
|
|
Terms of agreement description |
|
|
|
The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received.
|
The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received.
|
|
|
Repayment of grants | € |
|
|
|
|
|
148,500
|
|
Grant receivable | € |
|
|
|
|
|
€ 495,000
|
|
Fixed interest rate on lease |
|
|
|
2.89%
|
|
2.89%
|
|
In 2020 [Member] | Walloon Region Government [Member] | Colorectal Cancer Research Agreement [Member] |
|
|
|
|
|
|
|
Amount payable |
|
|
|
$ 53,765
|
|
|
|
Terms of agreement description |
|
|
|
The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received.
|
The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received.
|
|
|
Repayment of grants | € |
|
|
|
|
|
€ 278,830
|
|
Grant receivable | € |
|
|
|
|
|
€ 929,433
|
|
Fixed interest rate on lease |
|
|
|
4.34%
|
|
4.34%
|
|
In 2016 [Member] | ING [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
Purchase price for the property | € |
|
|
|
|
|
€ 1,120,000
|
|
Fixed interest rate on lease |
|
|
|
2.62%
|
|
2.62%
|
|
Lease payable |
|
|
|
$ 580,355
|
|
|
|
In 2016 [Member] | ING [Member] | Loan Agreement [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
Fixed interest rate |
|
|
|
2.62%
|
|
2.62%
|
|
Repayment of long-term loan amount | € |
|
|
|
|
€ 270,000
|
|
|
Principal balance payable |
|
|
|
$ 227,954
|
|
|
|
Loan agreement term |
|
|
|
15 years
|
15 years
|
|
|
In 2016 [Member] | Namur Invest [Member] | Loan Agreement [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
Maturity date |
|
|
|
December 2031
|
December 2031
|
|
|
Fixed interest rate |
|
|
|
4.85%
|
|
4.85%
|
|
Repayment of long-term loan amount | € |
|
|
|
|
€ 440,000
|
|
|
Loan agreement term |
|
|
|
7 years
|
7 years
|
|
|
Total long-term debt |
|
|
|
$ 194,720
|
|
|
|
In 2016 [Member] | DKFZ [Member] | Research Co-operation Agreement [Member] |
|
|
|
|
|
|
|
Collaborative obligations amount due |
|
|
|
$ 231,539
|
|
|
|
Lease agreement expire period |
|
|
|
5 years
|
5 years
|
|
|
Collaborative obligations amount | € |
|
|
|
|
|
€ 400,000
|
|
In 2017 [Member] | Namur Invest [Member] | Loan Agreement [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
Maturity date |
|
|
|
June 2021
|
June 2021
|
|
|
Fixed interest rate |
|
|
|
4.00%
|
|
4.00%
|
|
Repayment of long-term loan amount | € |
|
|
|
|
€ 350,000
|
|
|
Loan agreement term |
|
|
|
4 years
|
4 years
|
|
|
Total long-term debt |
|
|
|
$ 0
|
|
|
|
In 2017 [Member] | SOFINEX [Member] | Loan Agreement [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
Maturity date |
|
|
|
September 2024
|
September 2024
|
|
|
Fixed interest rate |
|
|
|
4.50%
|
|
4.50%
|
|
Repayment of long-term loan amount | € |
|
|
|
|
€ 1,000,000
|
|
|
Loan agreement term |
|
|
|
7 years
|
7 years
|
|
|
Total long-term debt |
|
|
|
$ 810,388
|
|
|
|
In 2019 [Member] | Taxes A&M University [Member] |
|
|
|
|
|
|
|
Repayment of long-term loan amount |
|
|
|
$ 400,000
|
|
|
|
Loan agreement term |
|
|
|
5 years
|
5 years
|
|
|
Collaborative obligations amount due |
|
|
|
$ 98,711
|
|
|
|
In 2019 [Member] | Namur Invest [Member] | Loan Agreement [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
Maturity date |
|
|
|
September 2024
|
September 2024
|
|
|
Fixed interest rate |
|
|
|
4.80%
|
|
4.80%
|
|
Repayment of long-term loan amount | € |
|
|
|
|
€ 500,000
|
|
|
Loan agreement term |
|
|
|
4 years
|
4 years
|
|
|
Total long-term debt |
|
|
|
$ 501,978
|
|
|
|
October 13, 2020 [Member] | Namur [Member] | Loan Agreement [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
Maturity date |
|
|
|
March 2031
|
March 2031
|
|
|
Fixed interest rate |
|
|
|
4.00%
|
|
4.00%
|
|
Repayment of long-term loan amount | € |
|
|
|
|
€ 830,000
|
|
|
Loan agreement term |
|
|
|
10 years
|
10 years
|
|
|
Total long-term debt |
|
|
|
$ 921,411
|
|
|
|
On September 16, 2020 [Member] | Bioinformatic Analytics Of Cell Free DNA [Member] |
|
|
|
|
|
|
|
Repayment of long-term loan amount | € |
|
|
|
|
€ 54,879
|
|
|
Total long-term debt |
|
|
|
92,749
|
|
|
|
Additional cost of company |
|
|
|
155,115
|
|
|
|
In 2019 [Member] | Collaborative Arrangement, Co-promotion [Member] |
|
|
|
|
|
|
|
Collaborative obligations amount due |
|
|
|
$ 0
|
|
|
|
Research collaboration agreement description |
|
|
|
Company entered into a research collaboration agreement with the University of Taiwan for a two-year period to collect a total of 1,200 samples for a cost to the Company of up to $320,000 payable over such period.
|
Company entered into a research collaboration agreement with the University of Taiwan for a two-year period to collect a total of 1,200 samples for a cost to the Company of up to $320,000 payable over such period.
|
|
|
October 25, 2019 [Member] | TAMU [Member] |
|
|
|
|
|
|
|
Non-controlling interest |
|
|
|
7.50%
|
7.50%
|
|
|
Equity interest |
|
|
|
12.50%
|
12.50%
|
|
|
Additional interest |
|
|
|
5.00%
|
5.00%
|
|
|
January 10, 2020 [Member] |
|
|
|
|
|
|
|
Common stock, restricted shares issued in exchange of purchased outstanding shares, value |
|
$ 333,969
|
|
|
|
|
|
Restricted shares issued | shares |
|
73,263
|
73,263
|
|
|
|
|
Common stock, restricted shares issued in exchange of purchased outstanding shares, shares | shares |
|
73,263
|
73,263
|
|
|
|
|
Weighted trading price per share | $ / shares |
|
$ 4.56
|
|
|
|
|
|
Repayment of debt | € |
|
|
€ 350,000
|
|
|
|
|
Common stock adjusted amount |
|
$ 357,000
|
|
|
|
|
|
Holdback period |
|
|
|
9 months
|
9 months
|
|
|
Holdback liabilities |
|
|
|
$ 55,404
|
|
|
|
Net liabilities |
|
$ 43,152
|
|
|
|
|
|
August 2021 [Member] |
|
|
|
|
|
|
|
Compensation expenses |
|
|
|
330,837
|
|
|
|
Accrued compensation |
|
|
|
229,900
|
|
|
|
July 1, 2022 [Member] |
|
|
|
|
|
|
|
Compensation expenses |
|
|
|
467,269
|
|
|
|
Accrued compensation |
|
|
|
116,121
|
|
|
|
Operating Lease Right of Use Obligations [Member] |
|
|
|
|
|
|
|
Short term lease costs |
|
|
|
$ 268,870
|
|
|
|
Weighted average discount rate |
|
|
|
4.49%
|
|
4.49%
|
|
Weighted average remaining lease term |
|
|
|
30 months
|
30 months
|
|
|
Payment of lease liabilities |
|
|
|
$ 151,003
|
|
|
|
Operating lease expense |
|
|
|
$ 151,635
|
|
|
|
Namur Innovation and Growth [Member] | In 2018 [Member] | Loan Agreement [Member] | Long-term Debt [Member] |
|
|
|
|
|
|
|
Maturity date |
|
|
|
June 2022
|
June 2022
|
|
|
Fixed interest rate |
|
|
|
4.00%
|
|
4.00%
|
|
Repayment of long-term loan amount | € |
|
|
|
|
€ 500,000
|
|
|
Loan agreement term |
|
|
|
4 years
|
4 years
|
|
|
Total long-term debt |
|
|
|
$ 130,938
|
|
|
|